Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 22, Issue 11
1 June 2016
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    The cover shows a section of a solid tumor in a mouse following mutation-specific TCR gene therapy. Intravital imaging shows the extravasation of erythrocytes, indicating vessel destruction only 1 day after mutation-specific T cells begin to infiltrate the cancer. For details, see the article by Leisegang and colleagues on page 2734 of this issue.
  • PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

CCR Translations

Is There a Future for AKT Inhibitors in the Treatment of Cancer?
Valerie M. Jansen; Ingrid A. Mayer; Carlos L. Arteaga
View articletitled, Is There a Future for AKT Inhibitors in the Treatment of Cancer?
Open the PDF for in another window
Neoantigen: A Long March toward Cancer Immunotherapy
Yang Liu
View articletitled, Neoantigen: A Long March toward Cancer Immunotherapy
Open the PDF for in another window

Molecular Pathways

Molecular Pathways: Targeting the PI3K Pathway in Cancer—BET Inhibitors to the Rescue
Elias E. Stratikopoulos; Ramon E. Parsons
View articletitled, Molecular Pathways: Targeting the PI3K Pathway in Cancer—BET Inhibitors to the Rescue
Open the PDF for in another window

CCR Focus

Phase I Testing: 60 Years in the Making
Susan E. Bates
View articletitled, Phase I Testing: 60 Years in the Making
Open the PDF for in another window
Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle
Pasi A. Jänne; Geoffrey Kim; Alice T. Shaw; Rajeshwari Sridhara; Richard Pazdur; Amy E. McKee
View articletitled, Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle
Open the PDF for in another window
Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management
Donna M. Dambach; Natalie E. Simpson; Thomas W. Jones; Richard J. Brennan; Richard Pazdur; Todd R. Palmby
View articletitled, Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management
Open the PDF for in another window
Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy
Lei Nie; Eric H. Rubin; Nitin Mehrotra; José Pinheiro; Laura L. Fernandes; Amit Roy; Stuart Bailey; Dinesh P. de Alwis
View articletitled, Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy
Open the PDF for in another window
Lessons Learned: Dose Selection of Small Molecule–Targeted Oncology Drugs
Julie M. Bullock; Atiqur Rahman; Qi Liu
View articletitled, Lessons Learned: Dose Selection of Small Molecule–Targeted Oncology Drugs
Open the PDF for in another window

Cancer Therapy: Clinical

Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Annett Linge; Steffen Löck; Volker Gudziol; Alexander Nowak; Fabian Lohaus; Cläre von Neubeck; Martin Jütz; Amir Abdollahi; Jürgen Debus; Inge Tinhofer; Volker Budach; Ali Sak; Martin Stuschke; Panagiotis Balermpas; Claus Rödel; Melanie Avlar; Anca-Ligia Grosu; Christine Bayer; Claus Belka; Steffi Pigorsch; Stephanie E. Combs; Stefan Welz; Daniel Zips; Frank Buchholz; Daniela E. Aust; Gustavo B. Baretton; Howard D. Thames; Anna Dubrovska; Jan Alsner; Jens Overgaard; Michael Baumann; Mechthild Krause; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG; for the DKTK-ROG
View articletitled, Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Supplementary data
Open the PDF for in another window
Author Choice
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Cynthia X. Ma; Cesar Sanchez; Feng Gao; Robert Crowder; Michael Naughton; Timothy Pluard; Allison Creekmore; Zhanfang Guo; Jeremy Hoog; A. Craig Lockhart; Austin Doyle; Charles Erlichman; Matthew J. Ellis
View articletitled, A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Supplementary data
Open the PDF for in another window
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
Kari B. Wisinski; Amye J. Tevaarwerk; Mark E. Burkard; Murtuza Rampurwala; Jens Eickhoff; Maria C. Bell; Jill M. Kolesar; Christopher Flynn; Glenn Liu
View articletitled, Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer
Open the PDF for in another window

Personalized Medicine and Imaging

Voxel Level Radiologic–Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer
Ghiam Yamin; Natalie M. Schenker-Ahmed; Ahmed Shabaik; Dennis Adams; Hauke Bartsch; Joshua Kuperman; Nathan S. White; Rebecca A. Rakow-Penner; Kevin McCammack; J. Kellogg Parsons; Christopher J. Kane; Anders M. Dale; David S. Karow
View articletitled, Voxel Level Radiologic–Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer
Supplementary data
Open the PDF for in another window
Author Choice
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Sibylle Loibl; Silvia Darb-Esfahani; Jens Huober; Alexander Klimowicz; Jenny Furlanetto; Bianca Lederer; Arndt Hartmann; Holger Eidtmann; Berit Pfitzner; Peter A. Fasching; Katharina Tiemann; Christian Jackisch; Keyur Mehta; Gunter von Minckwitz; Michael Untch; Carsten Denkert
View articletitled, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Supplementary data
Open the PDF for in another window

Cancer Therapy: Preclinical

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella; Saad S. Kenderian; Olga Shestova; Joseph A. Fraietta; Sohail Qayyum; Qian Zhang; Marcela V. Maus; Xiaobin Liu; Selene Nunez-Cruz; Michael Klichinsky; Omkar U. Kawalekar; Michael Milone; Simon F. Lacey; Anthony Mato; Stephen J. Schuster; Michael Kalos; Carl H. June; Saar Gill; Mariusz A. Wasik
View articletitled, The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Supplementary data
Open the PDF for in another window
Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Libo Zhang; Paula Marrano; Bing Wu; Sushil Kumar; Paul Thorner; Sylvain Baruchel
View articletitled, Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Supplementary data
Open the PDF for in another window
Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole
Joong Sup Shim; Ruo-Jing Li; Namandje N. Bumpus; Sarah A. Head; Kalyan Kumar Pasunooti; Eun Ju Yang; Junfang Lv; Wei Shi; Jun O. Liu
View articletitled, Divergence of Antiangiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole
Supplementary data
Open the PDF for in another window
Author Choice
The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Stephen Yiu Chuen Choi; Hui Xue; Rebecca Wu; Ladan Fazli; Dong Lin; Colin C. Collins; Martin E. Gleave; Peter W. Gout; Yuzhuo Wang
View articletitled, The <em>MCT4</em> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Supplementary data
Open the PDF for in another window
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation
Matthias Leisegang; Boris Engels; Karin Schreiber; Poh Yin Yew; Kazuma Kiyotani; Christian Idel; Ainhoa Arina; Jaikumar Duraiswamy; Ralph R. Weichselbaum; Wolfgang Uckert; Yusuke Nakamura; Hans Schreiber
View articletitled, Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation
Supplementary data
Open the PDF for in another window
Author Choice
Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer
Minoru Kato; Carmen A. Banuelos; Yusuke Imamura; Jacky K. Leung; Daniel P. Caley; Jun Wang; Nasrin R. Mawji; Marianne D. Sadar
View articletitled, Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer
Open the PDF for in another window

Biology of Human Tumors

MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Jordina Rovira; Kennosuke Karube; Alexandra Valera; Dolors Colomer; Anna Enjuanes; Lluís Colomo; Alejandra Martínez-Trillos; Eva Giné; Ivan Dlouhy; Laura Magnano; Julio Delgado; Antonio Martínez; Neus Villamor; Elías Campo; Armando López-Guillermo
View articletitled, <em>MYD88</em> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Supplementary data
Open the PDF for in another window
Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors
Damir Varešlija; Jean McBryan; Ailís Fagan; Aisling M. Redmond; Yuan Hao; Andrew H. Sims; Arran Turnbull; J.M. Dixon; Peadar Ó Gaora; Lance Hudson; Siobhan Purcell; Arnold D.K. Hill; Leonie S. Young
View articletitled, Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors
Supplementary data
Open the PDF for in another window
B7-H4(B7x)–Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Yu Yao; Hongxing Ye; Zengxin Qi; Lianjie Mo; Qi Yue; Aparajita Baral; Dave S.B. Hoon; Juan Carlos Vera; John D. Heiss; Clark C. Chen; Wei Hua; Jianmin Zhang; Kunlin Jin; Yin Wang; Xingxing Zang; Ying Mao; Liangfu Zhou
View articletitled, B7-H4(B7x)–Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Supplementary data
Open the PDF for in another window
Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma
Denise R. Minton; Leiping Fu; Nigel P. Mongan; Maria M. Shevchuk; David M. Nanus; Lorraine J. Gudas
View articletitled, Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma
Supplementary data
Open the PDF for in another window
The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer
Maximilian Lennartz; Sarah Minner; Sophie Brasch; Hilko Wittmann; Leonard Paterna; Katja Angermeier; Eray Öztürk; Rami Shihada; Mingu Ruge; Martina Kluth; Christina Koop; Waldemar Wilczak; Till Krech; Patrick Lebok; Corinna Wittmer; Hans Heinzer; Thomas Steuber; Meike Adam; Hartwig Huland; Markus Graefen; Alexander Haese; Ronald Simon; Guido Sauter; Thorsten Schlomm
View articletitled, The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer
Supplementary data
Open the PDF for in another window
MACC1 Induces Tumor Progression in Transgenic Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4
Clara Lemos; Markus S. Hardt; Manisha Juneja; Cynthia Voss; Susann Förster; Boris Jerchow; Wolfram Haider; Hendrik Bläker; Ulrike Stein
View articletitled, MACC1 Induces Tumor Progression in Transgenic Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4
Supplementary data
Open the PDF for in another window

Correction

Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
View articletitled, Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER<sup>+</sup> Breast Cancer
Open the PDF for in another window

Advertisement

Breaking
Tafasitamab Lowers Risk of Follicular Lymphoma Progression
9/11 First Responders Have Twofold Increase in Leukemia Precursor
Daratumumab Can Prevent Progression of Myeloma Precursor
View more recent articles
Latest News
Imlunestrant Delays Progression in Some Breast Cancers
“Digital Twins” May Improve Treatment Prediction
Prevention and Screening Preclude 80% of Cancer Deaths
View more recent articles
Research Watch
The Liver X Receptor Axis Balances Intestinal Regeneration and Tumorigenesis
Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive Bladder Cancer
Specialized Fibroblasts Shape T-Cell Environments in Lung Cancer
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept